Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.
Anaplastic Lymphoma Kinase
/ genetics
Animals
Cell Line, Tumor
Cell Proliferation
Cell Transformation, Neoplastic
/ genetics
Humans
Membrane Proteins
/ genetics
Mice
Mice, Inbred NOD
NIH 3T3 Cells
Nerve Tissue Proteins
/ genetics
Neuroblastoma
/ pathology
Oncogene Proteins, Fusion
/ genetics
Receptor Protein-Tyrosine Kinases
/ metabolism
Translocation, Genetic
/ genetics
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
23
04
2021
accepted:
25
03
2022
revised:
16
03
2022
pubmed:
13
4
2022
medline:
18
5
2022
entrez:
12
4
2022
Statut:
ppublish
Résumé
The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3-ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-Prkdc
Identifiants
pubmed: 35411036
doi: 10.1038/s41388-022-02301-1
pii: 10.1038/s41388-022-02301-1
doi:
Substances chimiques
Membrane Proteins
0
Nerve Tissue Proteins
0
Oncogene Proteins, Fusion
0
TENM3 protein, human
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2789-2797Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11.
pubmed: 20558371
pmcid: 3306838
doi: 10.1056/NEJMra0804577
Mazzocco K, Defferrari R, Sementa AR, Garaventa A, Longo L, De Mariano M, et al. Genetic abnormalities in adolescents and young adults with neuroblastoma: a report from the Italian Neuroblastoma group. Pediatr Blood Cancer. 2015;62:1725–32.
pubmed: 25925003
doi: 10.1002/pbc.25552
Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61:627–35.
pubmed: 24038992
doi: 10.1002/pbc.24777
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–17.
pubmed: 26304901
pmcid: 4567703
doi: 10.1200/JCO.2014.59.4648
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4.
pubmed: 8122112
doi: 10.1126/science.8122112
Roskoski R. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68:68–94.
pubmed: 23201355
doi: 10.1016/j.phrs.2012.11.007
Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T. et al. Role and targeting of anaplastic lymphoma kinase in cancer. Mol Cancer. 2018;17:30. https://doi.org/10.1186/s12943-018-0776-2 .
Okubo J, Takita J, Chen Y, Oki K, Nishimura R, Kato M, et al. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene. 2012;31:4667–76.
pubmed: 22249260
doi: 10.1038/onc.2011.616
Cazes A, Louis-Brennetot C, Mazot P, Dingli F, Lombard B, Boeva V, et al. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res. 2013;73:195–204.
pubmed: 23139213
doi: 10.1158/0008-5472.CAN-12-1242
Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, et al. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes Cancer. 2015;54:99–109.
pubmed: 25251827
doi: 10.1002/gcc.22223
Matsuno R, Akiyama K, Toyama D, Ikeda H, Yamamoto S. Adolescent pulmonary metastatic neuroblastoma with ALK rearrangement: a case report. Pediatr Int. 2020;62:507–9.
pubmed: 32297415
doi: 10.1111/ped.14117
Seki M, Nishimura R, Yoshida K, Shimamura T, Shiraishi Y, Sato Y, et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun. 2015;6:7557.
pubmed: 26138366
doi: 10.1038/ncomms8557
Tang Z, Wang L, Tang G, Medeiros LJ. Fluorescence in situ hybridization (FISH) for detecting anaplastic lymphoma kinase. Int J Mol Sci. 2019;20:3939.
Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet. 2017;49:1274–81.
pubmed: 28671687
doi: 10.1038/ng.3900
Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003;31:1007–14.
pubmed: 14585362
doi: 10.1016/S0301-472X(03)00260-1
Ceccon M, Metrlo MEB, Mologni L, Poggio T, Varecio LM, Menotti M, et al. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016;35:3854–65.
pubmed: 26657151
doi: 10.1038/onc.2015.456
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6:3314–22.
pubmed: 18089725
doi: 10.1158/1535-7163.MCT-07-0365
Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57:4720–44.
pubmed: 24819116
doi: 10.1021/jm500261q
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.
pubmed: 20979469
pmcid: 3014291
doi: 10.1056/NEJMoa1006448
Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175–82.
pubmed: 12384415
doi: 10.1182/blood-2001-12-0207
Arregui CO, Balsamo J, Lilien J. Regulation of signaling by protein-tyrosine phosphatases: potential roles in the nervous system. Neurochem Res. 2000;25:95–105.
pubmed: 10685609
doi: 10.1023/A:1007595617447
Young TR, Leamey CA. Teneurins: important regulators of neural circuitry. Int J Biochem Cell Biol. 2009;41:990–3.
pubmed: 18723111
doi: 10.1016/j.biocel.2008.06.014
Ziegler A, Corvalán A, Roa I, Brañes JA, Wollscheid B. Teneurin protein family: an emerging role in human tumorigenesis and drug resistance. Cancer Lett. 2012;326:1–7.
pubmed: 22841666
doi: 10.1016/j.canlet.2012.07.021
Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483:589–93.
pubmed: 22367537
doi: 10.1038/nature10910
Feng K, Zhou XH, Oohashi T, Mörgelin M, Lustig A, Hirakawa S, et al. All four members of the Ten-m/Odz family of transmembrane proteins form dimers. J Biol Chem. 2002;277:26128–35.
pubmed: 12000766
doi: 10.1074/jbc.M203722200
Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681–95.
pubmed: 11090048
doi: 10.1182/blood.V96.12.3681
Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174:661–70.
pubmed: 19147828
pmcid: 2630573
doi: 10.2353/ajpath.2009.080755
Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994;9:1567–74.
pubmed: 8183550
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.
pubmed: 17625570
doi: 10.1038/nature05945
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–203.
pubmed: 18083107
doi: 10.1016/j.cell.2007.11.025
Tabbó F, Barreca A, Piva R, Inghirami G. Group ET-CLS. ALK Signaling and target therapy in anaplastic large cell lymphoma. Front Oncol. 2012;2:41.
pubmed: 22649787
pmcid: 3355932
doi: 10.3389/fonc.2012.00041
Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623–37.
pubmed: 11607814
doi: 10.1038/sj.onc.1204594
Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008;99:2349–55.
pubmed: 19032370
doi: 10.1111/j.1349-7006.2008.00972.x
Richards MW, Law EW, Rennalls LP, Busacca S, O’Regan L, Fry AM, et al. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain. Proc Natl Acad Sci USA. 2014;111:5195–200.
pubmed: 24706829
pmcid: 3986153
doi: 10.1073/pnas.1322892111
Richards MW, O’Regan L, Roth D, Montgomery JM, Straube A, Fry AM, et al. Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. Biochem J. 2015;467:529–36.
pubmed: 25740311
doi: 10.1042/BJ20150039
Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14:6618–24.
pubmed: 18927303
doi: 10.1158/1078-0432.CCR-08-1018
Choi YL, Lira ME, Hong M, Kim RN, Choi SJ, Song JY, et al. A novel fusion of TPR and ALK in lung adenocarcinoma. J Thorac Oncol. 2014;9:563–6.
pubmed: 24736082
doi: 10.1097/JTO.0000000000000093
Amano Y, Ishikawa R, Sakatani T, Ichinose J, Sunohara M, Watanabe K, et al. Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3. Biochem Biophys Res Commun. 2015;457:457–60.
pubmed: 25596129
doi: 10.1016/j.bbrc.2015.01.014
Grande E, Bolós MV, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther. 2011;10:569–79.
pubmed: 21474455
doi: 10.1158/1535-7163.MCT-10-0615
Oohashi T, Zhou XH, Feng K, Richter B, Mörgelin M, Perez MT, et al. Mouse ten-m/Odz is a new family of dimeric type II transmembrane proteins expressed in many tissues. J Cell Biol. 1999;145:563–77.
pubmed: 10225957
pmcid: 2185078
doi: 10.1083/jcb.145.3.563
Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.
pubmed: 18097461
doi: 10.1038/nrc2291
Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199:330–58.
pubmed: 15095281
doi: 10.1002/jcp.10472
Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of non-Hodgkin’s lymphoma-asscociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997;17:2312–25.
pubmed: 9121481
pmcid: 232080
doi: 10.1128/MCB.17.4.2312
Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, et al. Nuclear localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res. 1998;58:1057–62.
pubmed: 9500471
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455:971–4.
pubmed: 18923524
doi: 10.1038/nature07399
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5.
pubmed: 18724359
pmcid: 2672043
doi: 10.1038/nature07261
Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–9.
pubmed: 18990089
doi: 10.1042/BJ20081834
George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–8.
pubmed: 18923525
pmcid: 2587486
doi: 10.1038/nature07397
Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–70.
pubmed: 18923523
doi: 10.1038/nature07398
Takita J. The role of anaplastic lymphoma kinase in pediatric cancers. Cancer Sci. 2017;108:1913–20.
pubmed: 28756644
pmcid: 5623752
doi: 10.1111/cas.13333
Kwak EL, Bang YJ, Cambridge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.
pubmed: 20979469
pmcid: 3014291
doi: 10.1056/NEJMoa1006448
Cambridge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379:2027–39.
doi: 10.1056/NEJMoa1810171
Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, et al. The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-Driven neuroblastoma. Cancer Discov. 2016;6:96–107.
pubmed: 26554404
doi: 10.1158/2159-8290.CD-15-1056
Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69:7338–46.
pubmed: 19723661
doi: 10.1158/0008-5472.CAN-08-4419
Hiwatari M, Taki T, Taketani T, Taniwaki M, Sugita K, Okuya M, et al. Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23). Oncogene. 2003;22:2851–5.
pubmed: 12743608
doi: 10.1038/sj.onc.1206389
Li Z, Dacic S, Pantanowitz L, Khalbuss WE, Nikiforova MN, Monaco SE. Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. Am J Clin Pathol. 2014;141:420–8.
pubmed: 24515771
doi: 10.1309/AJCPHF51LSPCAXTA